Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 44: 903-904, 1998;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liddle, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liddle, R. A.
Related Collections
Right arrow Endocrinology and Metabolism
(Clinical Chemistry. 1998;44:903-904.)
© 1998 American Association for Clinical Chemistry, Inc.


Editorial

On the Measurement of Cholecystokinin

Rodger A. Liddle

Department of Medicine, Box 3913, Duke University Medical Center, Durham, NC 27710, Fax 919-684-8857

A hormone is a chemical transmitter that is secreted from one part of the body and circulates in the bloodstream to reach a distant target in another part of the body where it exerts its biologic effect. At its inception, this was a revolutionary concept that gave birth to an entire physiological and, later, medical discipline. Early on, hormones were discovered by their biologic actions. However, the physiology of hormones could not be assessed without quantification. Fundamental to the study of hormones was the ability to measure concentrations in the blood. Although biological assays have been the cornerstone of endocrinologic measurements, the development of the radioimmunoassay (RIA) completely changed the field of endocrinology (1). The attractive features of RIA include (a) applicability to most hormones, (b) ease of performance, and (c) relatively low cost, as well as high degrees of (d) accuracy, (e) sensitivity, and (f) specificity.

Cholecystokinin (CCK) was discovered in 1928 on the basis of the ability of intestinal extracts to stimulate gallbladder contraction in dogs (2). Later it was recognized that CCK was a potent stimulant of pancreatic enzyme secretion (3). However, it was not until 1966, when CCK was purified, that the primary sequence was determined (4)(5). Early estimates of CCK-like activity in blood were based on biological assays such as pancreatic secretion or gallbladder contraction. However, these estimates were fraught with confounding problems that existed in whole animals, such as the effects of other hormones or neural influences. To circumvent these problems, a sensitive and specific in vitro bioassay was . . . [Full Text of this Article]


References




The following articles in journals at HighWire Press have cited this article:


Home page
Am. J. Clin. Nutr.Home page
C. de Graaf, W. A. Blom, P. A. Smeets, A. Stafleu, and H. F. Hendriks
Biomarkers of satiation and satiety
Am. J. Clinical Nutrition, June 1, 2004; 79(6): 946 - 961.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by the American Association for Clinical Chemistry.